Mois : mai 2019

CF2H, a Functional Group-Dependent Hydrogen-Bond Donor: Is It a More or Less Lipophilic Bioisostere of OH, SH, and CH3?


[1]

0 0
  • Y. Zafrani, G. Sod-Moriah, D. Yeffet, A. Berliner, D. Amir, D. Marciano, S. Elias, S. Katalan, N. Ashkenazi, M. Madmon, E. Gershonov, and S. Saphier, "CF2H, a Functional Group-Dependent Hydrogen-Bond Donor: Is It a More or Less Lipophilic Bioisostere of OH, SH, and CH3?", Journal of Medicinal Chemistry, vol. 62, pp. 5628-5637, 2019. http://dx.doi.org/10.1021/acs.jmedchem.9b00604
  • Sodium Methyl Carbonate as an Effective C1 Synthon. Synthesis of Carboxylic Acids, Benzophenones, and Unsymmetrical Ketones


    [1]

    0 0
  • T.E. Hurst, J.A. Deichert, L. Kapeniak, R. Lee, J. Harris, P.G. Jessop, and V. Snieckus, "Sodium Methyl Carbonate as an Effective C1 Synthon. Synthesis of Carboxylic Acids, Benzophenones, and Unsymmetrical Ketones", Organic Letters, vol. 21, pp. 3882-3885, 2019. http://dx.doi.org/10.1021/acs.orglett.9b00773
  • CF2H, a Functional Group-Dependent Hydrogen-Bond Donor: bioisosteric comparison to OH, SH, and CH3


    [1]

    0 0
  • Y. Zafrani, G. Sod-Moriah, D. Yeffet, A. Berliner, D. Amir, D. Marciano, S. Elias, S. Katalan, N. Ashkenazi, M. Madmon, E. Gershonov, and S. Saphier, "CF2H, a Functional Group-Dependent Hydrogen-Bond Donor: Is It a More or Less Lipophilic Bioisostere of OH, SH, and CH3?", Journal of Medicinal Chemistry, vol. 62, pp. 5628-5637, 2019. http://dx.doi.org/10.1021/acs.jmedchem.9b00604
  • The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future

    [1]
    0 0
  • S.M. Mennen, C. Alhambra, C.L. Allen, M. Barberis, S. Berritt, T.A. Brandt, A.D. Campbell, J. Castañón, A.H. Cherney, M. Christensen, D.B. Damon, J. Eugenio de Diego, S. García-Cerrada, P. García-Losada, R. Haro, J. Janey, D.C. Leitch, L. Li, F. Liu, P.C. Lobben, D.W.C. MacMillan, J. Magano, E. McInturff, S. Monfette, R.J. Post, D. Schultz, B.J. Sitter, J.M. Stevens, I.I. Strambeanu, J. Twilton, K. Wang, and M.A. Zajac, "The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future", Organic Process Research & Development, vol. 23, pp. 1213-1242, 2019. http://dx.doi.org/10.1021/acs.oprd.9b00140
  • Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes

    [1]
    0 0
  • L. Zhang, B. Riley-Gillis, P. Vijay, and Y. Shen, "Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes", Molecular Cancer Therapeutics, vol. 18, pp. 1302-1311, 2019. http://dx.doi.org/10.1158/1535-7163.MCT-18-1129